WAYNE, PA — Teleflex Incorporated (NYSE: TFX) is set to present three pivotal clinical studies on its BarrigelTM rectal spacer at the American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place in Washington, DC, from September 29 to October 2, 2024. These presentations aim to expand the clinical understanding of BarrigelTM, the sole commercial hyaluronic acid rectal spacer designed to shield the rectum during prostate cancer radiation therapy. BarrigelTM is a Non-Animal Stabilized Hyaluronic Acid (NASHA) spacer that significantly mitigates radiation to the rectum, aiming to enhance patient quality of life.
It has been shown to reduce radiation exposure effectively in 98.5% of prostate cancer patients with T1-T3b disease. The presentations include: Impact of Hyaluronic Acid (HA) Rectal Spacer Quality Score on Rectal Dosimetry and Gastrointestinal Toxicity Outcomes Date: October 1, 2:30-3:45 p.
m. ET, Hall C Focus: Retrospective review on the implant quality and GI toxicity in prostate cancer patients treated with hypofractionated EBRT. Rectal Wall Infiltration with Hyaluronic Acid Based Rectal Spacer Reversal Protocol Date: October 1, 2:30-3:45 p.
m. ET, Hall C Focus: Outcomes following rectal wall infiltration during BarrigelTM use. Hyaluronic Acid Rectal Spacer in Locally Recurrent Prostate Cancer Post-Radiation Date: October 1, 2:30-3:45 p.
m. ET, Hall C Focus: Evaluation of BarrigelTM in recurrent prostate cancer patients receiving SBRT. Teleflex will also.
